

Supplementary Table 1. Baseline characteristics of the whole sample and according to TL vs. no TL presence

Variable	All patients (n=784, 100%)	TL patients (n=174, 22.2%)	No TL patients (n=611, 77.8%)	P
General characteristic				
Male sex	410 (52.2)	128 (73.6)	282 (46.2)	<0.001
Age (yr)	72 (61–80)	63 (57–73)	75 (64–82)	<0.001
Admission NIHSS	16 (10–21)	16 (10–20)	17 (11–22)	0.604
Hypertension	565 (72)	126 (72.4)	439 (71.8)	0.884
Diabetes mellitus	229 (29.2)	47 (27)	182 (29.8)	0.477
Dyslipidemia	358 (45.6)	72 (41.4)	286 (46.8)	0.205
Smoking habit	145 (18.5)	54 (31.3)	91 (14.8)	<0.001
Atrial fibrillation	244 (31.1)	18 (10.3)	226 (37)	<0.001
Unknown stroke onset	249 (31.7)	57 (32.8)	192 (31.4)	0.739
Prior aspirin intake	238 (30.3)	48 (27.6)	190 (31.1)	0.374
Prior clopidogrel intake	36 (4.6)	10 (5.7)	26 (4.3)	0.407
Admission ASPECTS	9 (7–10)	8 (7–9)	9 (7–10)	0.001
Intravenous fibrinolysis	320 (40.8)	87 (50)	233 (38.1)	0.005
Symptoms onset–intravenous fibrinolysis time (min)	125 (97.5–172.5)	120 (95–180)	130 (100–170)	0.582
Cardioembolic cause*	393 (50.1)	21 (12.3)	372 (62.1)	<0.001
Atheromatous cause*	179 (22.8)	127 (74.3)	52 (8.7)	<0.001
DAWN or DEFFUSE 3 eligibility patients	249 (31.7)	57 (32.8)	192 (31.4)	0.739
Time and procedural characteristic				
Door–CT time (min)	20 (15–30)	20 (15–35)	20 (15–30)	0.483
Door–needle time (min)	45 (35–60)	45 (30–60)	50 (35–60)	0.280
Door–groin puncture time (min)	110 (75–150)	105 (70–160)	110 (80–148)	0.625
Groin–recanalization time (min)	25 (13–54)	50 (24–80)	21 (10–40)	<0.001
Symptoms onset–groin puncture time (min)	235 (160–375)	245 (145–385)	230 (160–370)	0.980
Number of passes	1 (1–3)	2 (1–3)	1 (1–3)	0.588
General anesthesia	52 (6.6)	15 (8.7)	37 (6.1)	0.473
Carotid stent	151 (19.2)	107 (61.5)	44 (7.2)	<0.001
Anterior communicating artery	186 (23.7)	104 (59.8)	82 (13.4)	<0.001
Posterior communicating artery	69 (8.8)	49 (28.2)	20 (3.3)	<0.001
Retrograde ophthalmic artery	38 (4.8)	34 (19.5)	4 (0.7)	<0.001
MT clopidogrel	8 (1)	3 (1.7)	5 (0.9)	0.362
MT reopro [†]	38 (4.8)	17 (9.8)	21 (3.4)	0.001

Values are presented as number (%) or median (interquartile range).

TL, tandem lesion; NIHSS, National Institutes of Heart Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; DAWN, DWI or CTP Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo; DEFFUSE 3, Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3; CT, computed tomography; MT, mechanical thrombectomy.

*According to Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification; [†]MT clopidogrel or reopro refers to clopidogrel and reopro administered during mechanical thrombectomy.